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Abstract
BACKGROUND: Oral temozolomide has shown similar efficacy to dacarbazine in phase III trials with
median progression-free survival (PFS) of 2.1 months. Bevacizumab has an inhibitory effect on the
proliferation of melanoma and sprouting endothelial cells. We evaluated the addition of bevacizumab to
temozolomide to improve efficacy in stage IV melanoma. PATIENTS AND METHODS: Previously
untreated metastatic melanoma patients with Eastern Cooperative Oncology Group performance status
of two or more were treated with temozolomide 150 mg/m(2) days 1-7 orally and bevacizumab 10
mg/kg body weight i.v. day 1 every 2 weeks until disease progression or unacceptable toxicity. The
primary end point was disease stabilisation rate [complete response (CR), partial response (PR) or stable
disease (SD)] at week 12 (DSR12); secondary end points were best overall response, PFS, overall
survival (OS) and adverse events. RESULTS: Sixty-two patients (median age 59 years) enrolled at nine
Swiss centres. DSR12 was 52% (PR: 10 patients and SD: 22 patients). Confirmed overall response rate
was 16.1% (CR: 1 patient and PR: 9 patients). Median PFS and OS were 4.2 and 9.6 months. OS (12.0
versus 9.2 months; P = 0.014) was higher in BRAF V600E wild-type patients. CONCLUSIONS: The
primary end point was surpassed showing promising activity of this bevacizumab/temozolomide
combination with a favourable toxicity profile. Response and OS were significantly higher in BRAF
wild-type patients.
For Peer Review
 
 
 
 
 
 
 
First-line temozolomide combined with bevacizumab in 
metastatic melanoma: A multicentre phase II trial (SAKK 
50/07) 
 
 
Journal: Annals of Oncology 
Manuscript ID: ANNONC-2010-1588 
Manuscript Type: Original Article 
Date Submitted by the 
Author: 
22-Oct-2010 
Complete List of Authors: von Moos, Roger; Kantonsspital Grauueünden, Department of 
Medicine Oncology 
Seifert, Burkhardt; University Hospital Basel, Oncology 
Simcock, Mathew; Swiss Group for Clinical Cancer Research, 
Statistics 
Goldinger, Simone; University Hospital Zurich, Oncology 
Gillessen, Silke; Kantonsspital, St. Gallen CH 
Ochsenbein, Adrian; University of Berne, Department of Clinical 
Research 
Michielin, Olivier; CHUV, Oncology 
Cathomas, Richard; Kantonsspital Graubünden, Medical Oncology 
Schlaeppi, Marc; Kantonsspital St.Gallen, Oncology / Hematology 
Moch, Holger; University Hospital of Zurich, Institute of Surgical 
Pathology, Department of Pathology 
Hans Schraml, Peter; University Hospital Zurich, Oncology 
Mihic-Probst, Daniela; University Hospital Zurich, Institute of 
Surgical Pathology, Department of Pathology 
Mamot, Christoph; Kantonsspital Aarau, Oncology 
Schönewolf, Nicola; University Hospital of Zürich, Department of 
Dermatology 
Dummer, Reinhard; University Hospital of Zurich, Department of 
Dermatology 
Keywords: 
metastatic melanoma, antiangiogenic therapy, bevacizumab, 
temozolomide, first line treatment  
Abstract: Background: Oral temozolomide has shown similar efficacy to 
Annals of Oncology
For Peer Review
dacarbazine in phase III trials with median progression free survival 
(PFS) of 2.1 months. Bevacizumab has an inhibitory effect on the 
proliferation of melanoma and sprouting endothelial cells. We 
evaluated the addition of bevacizumab to temozolomide to improve 
efficacy in stage IV melanoma. 
Patients and Methods: Previously untreated metastatic melanoma 
patients with ECOG performance status ≤2 were treated with 
temozolomide 150mg/m2 days 1-7 orally and bevacizumab 
10mg/kg body weight IV day 1 every 2 weeks until disease 
progression or unacceptable toxicity. The primary endpoint was 
disease stabilisation rate (CR, PR or SD) at week 12 (DSR12); 
secondary endpoints were best overall response, PFS, overall 
survival (OS) and adverse events. 
Results: Sixty-two patients (median age 59 years) enrolled at 9 
Swiss centres. DSR12 was 52% (PR: 10 patients, SD: 22 patients). 
Confirmed overall response rate was 16.1% (CR: 1 patient, PR: 9 
patients). Median PFS and OS was 4.2 and 9.6 months. OS (12.0 
vs. 9.2 months; p=0.014) was higher in BRAF V600E wild-type 
patients.  
Conclusion: The primary endpoint was surpassed showing 
promising activity of this Bevacizumab/temozolomide combination 
with a favourable toxicity profile. Response and OS were 
significantly higher in BRAF wild-type patients. 
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ABSTRACT 
Background: Oral temozolomide has shown similar efficacy to dacarbazine in phase 
III trials with median progression free survival (PFS) of 2.1 months. Bevacizumab has 
an inhibitory effect on the proliferation of melanoma and sprouting endothelial cells. 
We evaluated the addition of bevacizumab to temozolomide to improve efficacy in 
stage IV melanoma. 
Patients and Methods: Previously untreated metastatic melanoma patients with 
ECOG performance status ≤2 were treated with temozolomide 150mg/m2 days 1-7 
orally and bevacizumab 10mg/kg body weight IV day 1 every 2 weeks until disease 
progression or unacceptable toxicity. The primary endpoint was disease stabilisation 
rate (CR, PR or SD) at week 12 (DSR12); secondary endpoints were best overall 
response, PFS, overall survival (OS) and adverse events. 
Results: Sixty-two patients (median age 59 years) enrolled at 9 Swiss centres. 
DSR12 was 52% (PR: 10 patients, SD: 22 patients). Confirmed overall response rate 
was 16.1% (CR: 1 patient, PR: 9 patients). Median PFS and OS was 4.2 and 9.6 
months. OS (12.0 vs. 9.2 months; p=0.014) was higher in BRAF V600E wild-type 
patients.  
Conclusion: The primary endpoint was surpassed showing promising activity of this 
Bevacizumab/temozolomide combination with a favourable toxicity profile. Response 
and OS were significantly higher in BRAF wild-type patients. 
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INTRODUCTION 
Cutaneous melanoma today is considered a genetically heterogeneous disease 
characterised by a wide variation of genetic alterations, including the most frequent 
mutation in the BRAF gene [1]. This has resulted in molecular definition of melanoma 
subtypes [2].  Chemotherapy for metastatic melanoma remains disappointing. The 
median survival time is 6-9 months, depending on the bulk and location of disease at 
the time of tumour recurrence, and has not improved significantly in the last few 
decades with the currently available chemotherapy regimens. Dacarbazine, the 
generally accepted standard, has response rates in phase III trials of 9.8-12% [3,4]. 
Temozolomide is at least as effective in conventional dosing as it can cross the blood 
brain barrier and can be given orally [3]. Two phase II trials that combined extended 
dose temozolomide with thalidomide or with pegylated interferon α2b showed 
response rates of approximately 30% [5,6]. In analogy to the EORTC 18032 study [4] 
we decided to use the extended dosing temozolomide of 150 mg/m2 day 1-7 every 14 
days. 
Bevacizumab is a monoclonal antibody against vascular endothelial cell growth factor 
(VEGF), that has shown significant survival advantage when combined with 
chemotherapy in advanced colorectal and non-small cell lung cancer [7,8]. A 
significant advantage in progression-free survival (PFS) was attained in advanced 
breast [9] and non-small cell lung cancer [10] when administering bevacizumab in 
combination with chemotherapy and in renal cell cancer when combined with 
interferon [11,12]. Bevacizumab recognizes all isoforms of VEGF but does not 
recognise other peptide growth factors tested (fibroblast growth factor, epidermal 
growth factor, hepatocyte growth factor, platelet-derived growth factor and nerve 
growth factor). It may exert a direct anti-angiogenic effect by binding and clearing 
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VEGF from the tumour environment. Additional anti-tumour activity may be obtained 
via the effects of bevacizumab on tumour vasculature, interstitial pressure and blood 
vessel permeability that can lead to enhanced chemotherapy delivery to tumour cells.  
VEGF receptors were found in melanocytes as well as in malignant melanoma cells 
and the surrounding stromal cells [13]. It could be shown in several melanoma cell 
lines that treatment with Dacarbazine can cause higher secretion of IL8 and VEGF. 
Metastatic cell lines secreting high levels of IL8 and VEGF were more resistant to 
Dacarbazine treatment [14]. Exogenously added VEGF (10 ng/ml) was able to 
stimulate up to 40% increased proliferation of A375 melanoma cells following a 48 
hour period of quiescence, suggesting that VEGF indeed plays a role in autocrine, as 
well as paracrine stimulation of melanoma growth [15]. It was shown in human 
melanoma xenografts that anti-VEGF therapy inhibits melanoma growth [16]. 
However, tumour cells appear to express endothelial markers that do not respond to 
normal angiogenic control. In a recently published study it was shown that VEGF-A 
driven autocrine loop promotes human m lanoma cell ability to invade the 
extracellular matrix, which strongly supports the hypothesis that activation of VEGFR-
2 plays a primary role in this process [17]. Immunohistochemical studies have found 
that expression of VEGF in melanoma metastases is higher than in primary tumours 
and increased serum concentrations of VEGF have been found to correlate with 
tumour progression and survival [18]. A case series [19] as well as a few phase II 
studies of bevacizumab in combination with different non standard chemotherapy 
(nab-paclitaxel, paclitaxel as single agent or in combination with carboplatin) have 
been published so far [20-23]. One trial has combined bevacizumab with interferon 
α2b, another study tested the combination with everolimus [24,25]. The results of 
these trials are encouraging and warrant further evaluation of combination therapy of 
bevacizumab with other agents. 
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Considering all the points mentioned and in view of the fact that the combination of 
VEGF antibodies and standard chemotherapy can improve time to progression (TTP) 
and overall survival (OS) in different tumour entities, it appeared to us a logical step 
to investigate the combination of chemotherapy and bevacizumab in melanoma 
patients as well. Because temozolomide is a standard chemotherapy regime in 
metastatic melanoma, has a favorable side effect profile and non-overlapping toxicity 
with bevacizumab, we decided to test this combination in our trial. Especially, we 
were interested to evaluate the efficacy of this therapeutic approach in patients with 
BRAF positive compared to BRAF negative metastatic melanoma. 
 
PATIENTS AND METHODS 
Adult patients who had histologically confirmed stage IV metastatic melanoma; had 
measurable disease according to RECIST; had ECOG performance status of 2 or 
less; had haemoglobin ≥ 90 g/l (may be transfused to maintain or exceed this level), 
neutrophils ≥ 1.5 x 109/l, platelets ≥ 100 x 109/l, bilirubin ≤ 1.5 x ULN, ALAT and AP ≤ 
2.5 x ULN (≤ 5 x ULN acceptable in patients with liver metastases), serum creatinine 
< 177 µmol/l and had not received prior systemic chemotherapy were included. Prior 
cytokine or vaccine adjuvant therapy was allowed if it was completed more than 4 
weeks prior to trial registration. Prior vaccine therapy for stage IV as well as therapy 
of locoregional disease with perfusional therapy (limb and liver) was allowed as well. 
The main exclusion criteria were: patients with ocular melanoma, brain metastases 
[magnetic resonance imaging (MRI) mandatory], uncontrolled hypertension, use of 
full-dose oral or parenteral anticoagulants, thrombolytic agents or use of aspirin (> 
325 mg/day) or clopidogrel (> 75 mg/day). Major surgery within 30 days or minor 
surgery within 24 hours prior to registration, serious non-healing wound, active peptic 
ulcer, non-healing bone fracture or bleeding skin metastases were also considered 
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as exclusion criteria. Patients with history of abdominal disease such as fistula, 
gastrointestinal perforation or intra-abdominal abscess, not able to swallow tablets, 
receiving a treatment in a clinical trial within 30 days prior to registration, receiving 
concurrent treatment with other experimental drugs or other anti-cancer therapy, who 
had previous therapy with bevacizumab or other angiogenic inhibitors were not 
allowed to enter the trial. Pregnant or lactating women were excluded. The trial was 
approved by the local ethics review boards as well as by Swissmedic and was 
registered at the National Institute of Health (www.clinicaltrial.gov; identifier number: 
NCT00568048). All patients gave informed consent prior to any trial procedure. 
 
BRAF MUTATION STATUS – PCR-BASED METHOD 
In order to determine the mutation status for the amino acid exchange at position 
V600E of exon 15 of the BRAF gene, quantitative real-time PCR was performed by 
means of Taqman 7900HT Fast Real-Time PCR Systems (Applied Biosystems) 
subsequent to DNA-extraction from paraffin-embedded melanoma-tissue [26]. The 
exact method has been described elsewhere and has been used in a variety of 
tumour types [27]. 
 
TREATMENT 
Participating patients received a two drug regimen containing temozolomide 150 
mg/m2 on days 1-7 every 14 days orally and bevacizumab 10 mg/kg body weight 
intravenous over 90 minutes for the first infusion, 60 minutes for the second and 30 
minutes for the third and subsequent infusions every 14 days. In case of grade 3 
hematological toxicity two dose reduction for temozolomide was requested (dose -1: 
112.5 mg/m2, dose -2: 75 mg/m2). Therapy was given until progression, unacceptable 
toxicity or intolerability of either of the drugs. Prophylactic antiemetic treatment with a 
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5-HT3-antagonist was administered before temozolomide on day 1. From day 2, 
prophylaxis was replaced by metoclopramide 10 mg or domperidone 10 mg. Because 
continued administration of temozolomide has been associated with severe 
lymphocytopenia with increased risk for opportunistic infections, in particular 
pneumocystis jiorvecii pneumonia, prophylaxis with trimethoprim-sulfamethoxazole 
was recommended. 
 
CLINICAL ASSESSMENT 
Screening assessments included full physical examination and medical history, MRI 
of the brain, computed tomography (CT) as indicated for tumour assessment, 
hematology, chemistry testing and urinalysis. Physical examination, updates of the 
medical history, haematology (haemoglobin, neutrophils, platelets) and urine analysis 
were performed before each cycle. Tumour response was assessed by investigators 
according to the RECIST criteria 1.0 at the end of every 3 cycles (i.e., every 6 
weeks). Investigators were required to document all sites of disease at baseline. The 
longest diameter measurement of all lesions large enough to be reliably detected at 
baseline was summed at each tumour evaluation (i.e., sum of the longest diameters 
[SLD]). The first two tumour assessments after trial registration were reviewed by an 
independent, blinded, radiologist. The first documented partial response (PR) and 
complete response (CR) were confirmed by the next assessment six weeks later. 
Adverse events (AE) were graded according to National Cancer Institute’s Common 
Terminology Criteria of Adverse Events (CTCAE), version 3.0. 
 
STATISTICAL DESIGN AND ANALYSIS 
This single arm open label multicentre phase II trial used the Simon’s optimal two-
stage design with the primary endpoint being disease stabilisation rate at 12 weeks 
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(DRS12) after trial registration. The trial therapy would be considered promising if the 
proportion of patients with disease stabilisation [CR, PR or stable disease (SD)] was 
35% or more and uninteresting if 20% or less. Allowing for one interim analysis with 
80% power and a 5% significance level, the total sample size was 62 patients. This 
translates into the trial therapy being considered promising if, during the final 
analysis, 18 or more patients experience disease stabilisation at week 12. 
AEs were summarised by event type and grade over the total number of patients 
(worst recorded AE grade per patient).  
For secondary endpoints three time-to-event analyses were performed: PFS, 
duration of response stabilisation (RD) and OS. PFS was defined as the time from 
trial registration until either a disease progression or death with patients censored at 
the time of starting a second line therapy or the last time they were known to be alive 
without progression. RD included only patients with disease stabilisation (CR, PR or 
SD) and was read as the time from disease stabilisation until disease progression or 
death; patients were censored at the last time they were known to be alive and 
without disease progression if no event was observed. All time-to-event analyses 
were carried out using the intention-to-treat principle and estimated with the Kaplan-
Meier method. 
Other secondary endpoints included best overall response and confirmed response 
as well as the effect the BRAF mutation had on the primary and secondary 
endpoints. Between-group comparisons were carried out using the chi-squared test 
for categorical/binary endpoints and the log-rank test for time-to-event endpoints. 
The data was analysed in SAS (Statistical Analysis Systems, version 9.2). 
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RESULTS 
Between January 2008 and April 2009, 62 patients (40 male, 22 female) were 
enrolled. None of the patients were found ineligible or withdrew participation before 
the start of treatment. The median age at enrolment was 59 years (range: 29 - 82) 
and the median follow-up time was 20.1 (range: 1.7 – 32.0) months. All patients 
underwent at least one cycle of therapy. Further characteristics of these patients are 
presented in Table 1. 
 
Disease stabilisation rate at 12 weeks 
The unreviewed clinical DSR12 according to the investigators was 58% including 1 
patient with a CR, 11 patients with a PR and 24 patients with SD. The independently 
reviewed DSR12 was 52% (10 PR, 22 SD). 
 
Overall best response 
The independently reviewed and confirmed objective response rate was 16.1% with 1 
patient with CR and 9 patients with PR. Patients with elevated LDH (28 patients) did 
not have a higher response rate than patients with LDH within normal range (33 
patients) (6.6% versus 9.8%, p value: 0.4899). No correlation between experiencing 
hypertension and response rate could be seen. At the end of the observation period 
1 out of 32 patients with reviewed disease stabilisation at 12 weeks had not 
experienced progression and was censored. Median RD was 6.1 months [95% 
confidence interval (CI): 5.3, 8.1]. Maximum percentage change in the SLD from trial 
registration is depicted by a waterfall plot: Figure 1. 
 
Progression free - and overall survival 
Median PFS was 4.2 months (95% CI: 2.7, 5.4) (Figure 2) and median RD was 4.4 
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months (95% CI: 4.1, 5.7). At 6 months 33% (95% CI: 21.7, 44.8) of the patients 
survived without experiencing disease progression. The 6 months survival probability 
was 77.4% (95% CI: 64.9, 86.0) and the median OS was 9.6 months (95% CI: 8.0, 
11.9) (Figure 2). Non-statistically significant differences in median OS was observed 
when stratified by LDH level: normal 11.5 months (95% CI: 8.3, 13.6) vs. elevated 8.8 
months (95% CI: 6.5, 11.8); p = 0.1746 (Figure 3).  
 
Toxicity 
The toxicity analysis was based on all treated patients (n = 62). The majority of 
observed AEs were mild to moderate (i.e., grades 1 or 2) in severity. Thirty-two 
percent of all patients experienced a serious adverse event during the trial. The most 
common haematological grade 3 and 4 AEs were thrombocytopenia (6 patients, 
9.7%) and neutropenia (4 patients, 6.5%). Non-haematological AEs grade 3 were 
hypertension (7 patients, 11.3%), fatigue (5 patients, 8.1%), haemorrhage (3 patients, 
4.8%), nausea (3 patients, 4.8%) and vomiting (2 patients, 3.2%). Other toxicities 
were rare (Table 2). Of the 56 patients who died since study entry, 51 deaths were 
attributed to disease progression, one was the patient decision, two are unknown and 
two deaths were attributed to the trial drugs, one patient died with extensive 
abdominal tumour burden and bowel perforation, another patient died with pulmonary 
infection without leuco- or lymphopenia. 
 
BRAF analysis 
Of the 44 BRAF status results available for analysis; 22 patients had the BRAF 
V600E mutation and 22 were BRAF wild-type. Based on the independent response 
review, a statistically significant association was found between BRAF status and the 
unconfirmed 12 weeks response favouring a response in the wild-type group; p = 
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0.0088. Median PFS time in the mutated group was 4.0 months (95% CI: 1.7, 5.4) vs. 
5.4 months (95% CI: 2.6, 8.2) in the wild-type group; p = 0.0556. Median duration of 
disease stabilisation was 4.2 (95% CI: 3.0, 5.5) vs. 4.1 (95% CI: 2.7, 6.9) months 
between the mutated (n = 15) and wild-type (n = 17) groups respectively; p = 0.7292. 
A statistically significant difference was found between the groups regarding OS; 
median OS being 9.2 months (95% CI: 6.5, 11.9) in the mutated group compared 
with 12.0 months (95% CI: 7.4, 16.4) in the wild-type group (p = 0.0137) (Figure 4). 
Other prognostic biomarkers for metastatic melanoma such as LDH, performance 
status and age did not differ significantly between the BRAF mutated versus BRAF 
wild-type groups. Due to low numbers, no multivariable analyses are performed 
regarding BRAF status. 
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DISCUSSION 
No significant advances in the treatment of metastatic melanoma have been 
achieved in the last three decades. Despite several promising results in phase II 
trials, all phase III trials have reported negative results. 
This multicentre single arm phase II trial surpassed its primary endpoint of 18 or more 
patients with a DSR12 with an impressive 32/62 patients having confirmed, reviewed 
disease stabilisation as defined in our trial. Our response rate of 16.1% is in the same 
range as reported for single agent temozolomide conventional [3] (13.5%) and 
extended dosing schedule [4] (14.5%), despite having studied a population at higher 
risk by including patients with LDH > 2 ULN (16%) and/or ECOG performance status 
of 2: (7%). The median PFS of 4.2 months compares favourably with the PFS seen in 
single agent temozolomide trials (1.9 - 2.3 months). The median OS of 
temozolomide+bevacizumab was in the range of single agent temozolomide (9.6 
months versus 7.7 - 9.1 months) [3,4]. The extent of response rate as well as PFS is 
comparable to other trials that have added bevacizumab to conventional 
chemotherapy in melanoma patients [22,23]. In the only randomised phase II trial of 
its kind, carboplatin and paclitaxel (CPP) showed a PFS of 4.2 months versus 5.6 
months (p = 0.14) when adding bevacizumab (CPB) [22]. In another single arm 
phase II trial with CPB dosing paclitaxel weekly the PFS was in the same range (6.5 
months) [23]. Even though the absolute numbers of PFS are slightly higher in the 
combination chemotherapy backbone with CPB, the extent of improvement with 
bevacizumab when combined with temozolomide seems to be higher compared to 
other chemotherapy backbone. In addition, the side effects of single agent oral 
temozolomide are lower and seem to be better tolerable for the patients. In contrast 
to most melanoma trials our patients with elevated LDH showed higher response 
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rates and a statistically equal OS to the group with normal LDH value. This raises the 
hypothesis whether patients at high risk with rapidly progressive disease may 
particularly profit more from the addition of bevacizumab, which is in line with the 
results of the BEAM trial [22].  
Patients with a BRAF wild-type had better progression free- (borderline significance), 
overall- survival and response rate than patients with BRAF mutation. It remains to 
be determined whether this mutation is only a prognostic or also a predictive 
biomarker. Since there are new promising targeted therapies for BRAF mutant 
patients such as PLX4032 in phase III trials it appears appealing to re-evaluate these 
findings in BRAF wild-type patients.  
The treatment was generally well tolerated. The incidence of serious adverse events 
in our trial was 32%, which is comparable to the 30% observed in single agent 
temozolomide [4]. Bevacizumab specific side effects were in the range known from 
other trials; no new or unexpected toxicities occurred. The good tolerability is of 
utmost importance in a disease where survival is mostly short and the quality of life of 
the remaining weeks is crucial for the patients. 
 
In summary, the results of our trial suggest that the combination of an alkylating 
agent such as temozolomide with an agent that specifically targets VEGF might be a 
valid and interesting therapeutic strategy for patients with metastatic melanoma. A 
phase III trial stratifying for LDH level as well as for BRAF status is urgently 
warranted in a disease where no satisfactory first line treatment exists. 
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Table 1: Patient baseline characteristics 
Characteristics Frequency (%) [n = 62] 
Median Age: years (range) 59 (29-84) 
Sex:  
 Male 40 (64.5) 
 Female 22 (35.5) 
ECOG Performance status:  
 0 39 (62.9) 
 1 19 (30.7) 
 2 4 (6.5) 
Grade of metastatic disease:  
 M1a 4 (6.5) 
 M1b 12 (19.4) 
 M1c 46 (74.2) 
LDH before therapy:  
 Missing 1 (1.6) 
 LDH ≤ ULN  33 (53.2) 
 LDH > ULN, ≤ 2 x ULN  18 (29) 
 LDH > 2 x ULN 10 (16.1) 
BRAF V600E status:  
 Wild-type 22 (35.5) 
 Mutated 22 (35.5) 
 No amplification 18 (29.0) 
. 
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Table 2: Adverse events (worst grade observed per patient) 
 CTCAE Grade [n (%)] 
Adverse Event Grade 3 Grade 4 Grade 5 
ALT - 1 (2) - 
AST 1 (2) - - 
Alkaline phosphatase 1 (2) - - 
Anorexia 1 (2) - - 
Bilirubin 1 (2) - - 
Confusion - 1 (2) - 
Constipation 2 (3) - - 
Diabetes 1 (2) - - 
Diarrhea 1 (2) - - 
Extensive abdominal tumour burden and bowel 
perforation 
- - 1 (2) 
Fatigue 4 (7) 1 (2) - 
Fracture 1 (2) - - 
GGT 1 (2) - - 
Hand-foot 1 (2) - - 
Haemorrhage 3 (5) - - 
Hypertension 7 (11) - - 
Infection with unknown ANC - NOS 1 (2) - - 
Leukocytes 2 (3) - - 
Lymphopenia 1 (2) 1 (2) - 
Nausea 3 (5) - - 
Neutrophils 3 (5) 1 (2) - 
Pain 7 (11) 1 (2) - 
Platelets 4 (7) 2 (3) - 
Pulmonary infection without leuco- or lymphopenia - - 1 (2) 
Thrombosis/thrombus/embolism - 1 (2) - 
Trismus 1 (2) - - 
Vomiting 2 (3) - - 
Only grade 3 and 4 adverse events shown 
CTCAE: Common terminology criteria for adverse events (version 3.0). 
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Figure 1: Waterfall plot of maximal percentage change in sum of longest diameter of 
target tumour lesion(s) size from baseline 
 
Figure 2: Kaplan-Meier plot of progression free survival and overall survival 
 
 
Figure 3: Kaplan-Meier plot of overall survival stratified by normal LDH and elevated 
LDH 
 
 
 
Figure 4: Kaplan-Meier plot of overall survival stratified by BRAF wild-type and BRAF 
mutation 
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Kaplan-Meier plot of overall survival stratified by normal LDH and elevated LDH  
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Kaplan-Meier plot of overall survival stratified by BRAF wild-type and BRAF mutation  
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